The British journal of psychiatry : the journal of mental science
February 1, 2025
Allan H Young, Pierre-Michel Llorca, Andrea Fagiolini et al.
7 citations
In people with treatment-resistant depression, esketamine nasal spray outperformed quetiapine extended release across multiple measures. Sensitivity analyses using different definitions of remission and relapse consistently favored esketamine, with relative risks for the primary endpoint ranging from 1.462 to 1.737 and for the key secondary endpoint from 1.417 to 1.838. Esketamine also shortened time to first remission by 71% and confirmed remission by 66%. The robustness of the original ESCAPE-TRD trial findings was confirmed.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
May 1, 2024
Víctor De la Peña-arteaga, Marta Cano, Daniel Porta-Casteràs et al.
5 citations
In patients with obsessive-compulsive disorder (OCD) undergoing a 3-month mindfulness-based cognitive therapy (MBCT) programme, distinct baseline brain connectivity patterns were associated with four clinical domains: positive affect, negative affect, anxiety sensitivity, and rumination. Key brain nodes—the precuneus and frontopolar cortex—within the ventral default mode network and frontostriatal network showed predictive and response associations with clinical changes. MBCT may modulate connectivity in these networks, potentially reducing symptoms across domains. These network-based biomarkers could help personalize treatment and identify patients most likely to benefit from MBCT.
Revista de psiquiatria y salud mental
January 1, 2023
Neus Miquel-Giner, Muriel Vicent-Gil, Ignacio Martínez-zalacaín et al.
4 citations
About 40-50% of patients with obsessive-compulsive disorder (OCD) continue to experience obsessions and compulsions after first-line treatments. Mindfulness-based cognitive therapy (MBCT) is proposed as an augmentation strategy to help patients decentre from distressful thoughts, potentially increasing non-reactivity and reducing compulsions. This randomized clinical trial of 60 OCD patients who did not respond to first-line treatments will compare an MBCT program (10 weekly 120-minute sessions) with treatment as usual. The primary outcome is change in OCD severity, measured by clinician and self-reported assessments. Comprehensive evaluations will include comorbid clinical variables, neuropsychological functioning, thought content, and structural and functional neuroimaging at baseline and post-intervention. This is the first RCT in this population to examine clinical, neuropsychological, and neuroimaging variables together to identify neural patterns associated with MBCT response.